NBIX · NASDAQ · STOCK
Neurocrine Biosciences
$163.95
52W $122.14 – $186.12
63/100
$16.43B
23.2
0.39
Is NBIX Bullish or Bearish?
Bullish.
Innellis AI committee rates Neurocrine Biosciences (NBIX) Buy with a composite score of 63/100
, based on 6 analysts with 50% agreement.
Last updated August 09, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.64 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.36 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 09, 2026
Overall Committee Score
63/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 22%
of 95 Healthcare peers
Value Analyst
neutral
59
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 21.1% shows genuine earnings power backing the valuation
− Price-to-book of 4.3x prices in significant intangible value
Growth Analyst
bullish
84
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.4% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 16.0% signals elevated volatility
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 63.4 to 63.4.
Comparing 2026-08-08 to 2026-08-09 (1 day apart).
Technical Analysis
RSI (14)
37.5
Neutral
MACD Histogram
-2.340
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.18
Inside Bands
Price vs Moving Averages
EMA 9
$167.35
Below
EMA 21
$170.07
Below
EMA 50
$166.24
Below
EMA 200
$149.35
Above
Fundamental Analysis
Valuation
74
Growth
85
Profitability
93
Financial Health
95
Cash Flow
70
Valuation
P/E Ratio
23.2×
P/B Ratio
4.47×
PEG Ratio
0.23
Dividend Yield
0.00%
52W High
$186.12
52W Low
$122.14
Quality & Growth
ROE
1471.2%
ROA
1033.4%
Gross Margin
9796.7%
Operating Margin
2338.2%
Revenue Growth YoY
—
Debt / Equity
0.11
AI Fundamental Assessment
P/E ratio of 23.2 (inexpensive relative to a 15-40x range); Price-to-book of 4.5x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.7%; Return on assets of 10.3%; Net margin of 20.9%; Gross margin of 98.0%; Current ratio of 1.87 (healthy short-term liquidity); Debt-to-equity of 0.11; Free cash flow per share is positive (8.62); Most recent quarter beat estimates by 175.3%; 5 consecutive earnings beats; EPS growth accelerating (-27.2% -> +105.0% QoQ); Average YoY EPS growth of 168.9%; Analyst estimates falling over recent quarters
Get the Full NBIX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →